201 related articles for article (PubMed ID: 35638715)
1. Clinical Significance of Gene Mutations and Polymorphic Variants and their Association with Prostate Cancer Risk in Polish Men.
Heise M; Jarzemski P; Nowak D; Bąk A; Junkiert-Czarnecka A; Pilarska-Deltow M; Borysiak M; Pilarska B; Haus O
Cancer Control; 2022; 29():10732748211062342. PubMed ID: 35638715
[No Abstract] [Full Text] [Related]
2. G84E germline mutation in HOXB13 gene is associated with increased prostate cancer risk in Polish men.
Heise M; Jarzemski P; Bąk A; Junkiert-Czarnecka A; Pilarska-Deltow M; Haus O
Pol J Pathol; 2019; 70(2):127-133. PubMed ID: 31556563
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes.
Kote-Jarai Z; Mikropoulos C; Leongamornlert DA; Dadaev T; Tymrakiewicz M; Saunders EJ; Jones M; Jugurnauth-Little S; Govindasami K; Guy M; Hamdy FC; Donovan JL; Neal DE; Lane JA; Dearnaley D; Wilkinson RA; Sawyer EJ; Morgan A; Antoniou AC; Eeles RA;
Ann Oncol; 2015 Apr; 26(4):756-761. PubMed ID: 25595936
[TBL] [Abstract][Full Text] [Related]
4. A personalised approach to prostate cancer screening based on genotyping of risk founder alleles.
Cybulski C; Wokołorczyk D; Kluźniak W; Kashyap A; Gołąb A; Słojewski M; Sikorski A; Puszyński M; Soczawa M; Borkowski T; Borkowski A; Antczak A; Przybyła J; Sosnowski M; Małkiewicz B; Zdrojowy R; Domagała P; Piotrowski K; Menkiszak J; Krzystolik K; Gronwald J; Jakubowska A; Górski B; Dębniak T; Masojć B; Huzarski T; Muir KR; Lophatananon A; Lubiński J; Narod SA;
Br J Cancer; 2013 Jun; 108(12):2601-9. PubMed ID: 23722471
[TBL] [Abstract][Full Text] [Related]
5. A novel founder CHEK2 mutation is associated with increased prostate cancer risk.
Cybulski C; Huzarski T; Górski B; Masojć B; Mierzejewski M; Debniak T; Gliniewicz B; Matyjasik J; Złowocka E; Kurzawski G; Sikorski A; Posmyk M; Szwiec M; Czajka R; Narod SA; Lubiński J
Cancer Res; 2004 Apr; 64(8):2677-9. PubMed ID: 15087378
[TBL] [Abstract][Full Text] [Related]
6. Germline genetic variants in men with prostate cancer and one or more additional cancers.
Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of the HOXB13 G84E mutation in Danish men undergoing radical prostatectomy and its correlations with prostate cancer risk and aggressiveness.
Storebjerg TM; Høyer S; Kirkegaard P; Bro F; ; Ørntoft TF; Borre M; Sørensen KD
BJU Int; 2016 Oct; 118(4):646-53. PubMed ID: 26779768
[TBL] [Abstract][Full Text] [Related]
8. Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers.
Lotan TL; Torres A; Zhang M; Tosoian JJ; Guedes LB; Fedor H; Hicks J; Ewing CM; Isaacs SD; Johng D; De Marzo AM; Isaacs WB
Oncotarget; 2017 Apr; 8(14):22772-22782. PubMed ID: 28186998
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of the HOXB13 G84E prostate cancer risk allele in men treated with radical prostatectomy.
Beebe-Dimmer JL; Isaacs WB; Zuhlke KA; Yee C; Walsh PC; Isaacs SD; Johnson AM; Ewing CE; Humphreys EB; Chowdhury WH; Montie JE; Cooney KA
BJU Int; 2014 May; 113(5):830-5. PubMed ID: 24148311
[TBL] [Abstract][Full Text] [Related]
10. Testing for the recurrent HOXB13 G84E germline mutation in men with clinical indications for prostate biopsy.
Schroeck FR; Zuhlke KA; Siddiqui J; Siddiqui R; Cooney KA; Wei JT
J Urol; 2013 Mar; 189(3):849-53. PubMed ID: 23036981
[TBL] [Abstract][Full Text] [Related]
11. Confirmation of the HOXB13 G84E germline mutation in familial prostate cancer.
Breyer JP; Avritt TG; McReynolds KM; Dupont WD; Smith JR
Cancer Epidemiol Biomarkers Prev; 2012 Aug; 21(8):1348-53. PubMed ID: 22714738
[TBL] [Abstract][Full Text] [Related]
12. Selected Aspects of Molecular Diagnostics of Constitutional Alterations in BRCA1 and BRCA2 Genes Associated with Increased Risk of Breast Cancer in the Polish Population.
Górski B
Hered Cancer Clin Pract; 2006 Aug; 4(3):142-52. PubMed ID: 20223018
[TBL] [Abstract][Full Text] [Related]
13. A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk.
Karlsson R; Aly M; Clements M; Zheng L; Adolfsson J; Xu J; Grönberg H; Wiklund F
Eur Urol; 2014 Jan; 65(1):169-76. PubMed ID: 22841674
[TBL] [Abstract][Full Text] [Related]
14. A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer.
Cybulski C; Wokołorczyk D; Huzarski T; Byrski T; Gronwald J; Górski B; Debniak T; Masojć B; Jakubowska A; Gliniewicz B; Sikorski A; Stawicka M; Godlewski D; Kwias Z; Antczak A; Krajka K; Lauer W; Sosnowski M; Sikorska-Radek P; Bar K; Klijer R; Zdrojowy R; Małkiewicz B; Borkowski A; Borkowski T; Szwiec M; Narod SA; Lubiński J
J Med Genet; 2006 Nov; 43(11):863-6. PubMed ID: 17085682
[TBL] [Abstract][Full Text] [Related]
15. Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer.
Truong H; Breen K; Nandakumar S; Sjoberg DD; Kemel Y; Mehta N; Lenis AT; Reisz PA; Carruthers J; Benfante N; Joseph V; Khurram A; Gopalan A; Fine SW; Reuter VE; Vickers AJ; Birsoy O; Liu Y; Walsh M; Latham A; Mandelker D; Stadler ZK; Pietzak E; Ehdaie B; Touijer KA; Laudone VP; Slovin SF; Autio KA; Danila DC; Rathkopf DE; Eastham JA; Chen Y; Morris MJ; Offit K; Solit DB; Scher HI; Abida W; Robson ME; Carlo MI
Eur Urol; 2023 Jan; 83(1):29-38. PubMed ID: 36115772
[TBL] [Abstract][Full Text] [Related]
16. A risk of breast cancer in women - carriers of constitutional CHEK2 gene mutations, originating from the North - Central Poland.
Bąk A; Janiszewska H; Junkiert-Czarnecka A; Heise M; Pilarska-Deltow M; Laskowski R; Pasińska M; Haus O
Hered Cancer Clin Pract; 2014 Apr; 12(1):10. PubMed ID: 24713400
[TBL] [Abstract][Full Text] [Related]
17. Germline Variants of Prostate Cancer in Japanese Families.
Hayano T; Matsui H; Nakaoka H; Ohtake N; Hosomichi K; Suzuki K; Inoue I
PLoS One; 2016; 11(10):e0164233. PubMed ID: 27701467
[TBL] [Abstract][Full Text] [Related]
18. [Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer].
Matveev VB; Kirichek AA; Filippova MG; Savinkova AV; Khalmurzaev OA; Lyubchenko LN
Urologiia; 2019 Dec; (5):79-85. PubMed ID: 31808637
[TBL] [Abstract][Full Text] [Related]
19. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
20. HOXB13 mutations in a population-based, case-control study of prostate cancer.
Stott-Miller M; Karyadi DM; Smith T; Kwon EM; Kolb S; Stanford JL; Ostrander EA
Prostate; 2013 May; 73(6):634-41. PubMed ID: 23129385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
